https://doi.org/10.4081/hmr.v1i9.331

Heparin effects in metastasis and Trousseau's syndrome: anticoagulation is not the primary mechanism

Vol. 1 No. 9: 3rd International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, October 14-16, 2005
Published: June 3, 2009
Abstract Views: 295
PDF: 196
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

JL Stevenson
support@pagepress.org
SH Choi
M Wahrenbrock
A Varki
NM Varki
The existence of recurring and successful International Conference on Thrombosis and Hemostasis Issues in Cancer arises is due to the well-documented and frequent clinical association between malignancy and excessive thrombosis in humans. Unfractionated heparin (UFH) has been the classic anticoagulant of choice to treat cancer patients with thrombosis, and recent studies have indicated that UFH could be replaced by various low molecular weight heparins (LMWHs), which have several advantages for clinical use. Heparins are also the agent of choice in treating patients with classic Trousseau's Syndrome (spontaneous migratory thrombophlebitis with microangiopathic symptoms, typically associated with mucin-producing carcinomas). Meanwhile, UFH has been shown to reduce tumor metastasis in many murine models. Also, retrospective and post-hoc analyses of clinical studies suggest that UFH and some LMWHs might improve outcomes in human cancer.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Stevenson, J., Choi, S., Wahrenbrock, M., Varki, A., & Varki, N. (2009). Heparin effects in metastasis and Trousseau’s syndrome: anticoagulation is not the primary mechanism. Hematology Meeting Reports (formerly Haematologica Reports), 1(9). https://doi.org/10.4081/hmr.v1i9.331
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).